PLUS - 医索

找到约 86 条结果

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer an open-label, single-arm, phase II trial

医客学院 - 药物研究

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310) a randomised, open-label, international phase 3 study

医客学院 - 药物研究

A Phase 12 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma

医客学院 - 其他

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer A multicenter phase 3 trial (RATIONALE-309)

医客学院 - 其他

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma a prospective cohort study

医客学院 - 指南共识

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

医客学院 - 药物研究

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer the phase 2 platform NEOSTAR trial

医客学院 - 药物研究

slides-Oneyear_duration_of_nivolumab_plus_ipilimumab_in_p

医客学院 - 会议报告集

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma a randomized, double-blind phase 3 trial

医客学院 - 药物研究

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer 5-Year Update of the Phase III KEYNOTE-407 Study

医客学院 - 药物研究

今日实时热搜